Literature DB >> 22360714

Pharmacoeconomics.

Dyfrig A Hughes1.   

Abstract

Pharmacoeconomics is an essential component of health technology assessment and the appraisal of medicines for use by UK National Health Service (NHS) patients. As a comparatively young discipline, its methods continue to evolve. Priority research areas for development include methods for synthesizing indirect comparisons when head-to-head trials have not been performed, synthesizing qualitative evidence (for example, stakeholder views), addressing the limitations of the EQ-5D tool for assessing quality of life, including benefits not captured in quality-adjusted life years (QALYs), ways of assessing valuation methods (for determining utility scores), extrapolation of costs and benefits beyond those observed in trials, early estimation of cost-effectiveness (including mechanism-based economic evaluation), methods for incorporating the impact of non-adherence and the role of behavioural economics in influencing patients and prescribers.
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22360714      PMCID: PMC3391529          DOI: 10.1111/j.1365-2125.2012.04247.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

Review 1.  Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?

Authors:  D A Hughes; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Comparing utility scores before and after hearing-aid provision : results according to the EQ-5D, HUI3 and SF-6D.

Authors:  Garry R Barton; John Bankart; Adrian C Davis; Quentin A Summerfield
Journal:  Appl Health Econ Health Policy       Date:  2004       Impact factor: 2.561

3.  Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review.

Authors:  Susanne Hartz; Jürgen John
Journal:  Int J Technol Assess Health Care       Date:  2008       Impact factor: 2.188

Review 4.  Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence.

Authors:  Louise Longworth; Mark J Sculpher; Laura Bojke; Jonathan C Tosh
Journal:  Int J Technol Assess Health Care       Date:  2011-03-29       Impact factor: 2.188

5.  Judging nudging: can nudging improve population health?

Authors:  Theresa M Marteau; David Ogilvie; Martin Roland; Marc Suhrcke; Michael P Kelly
Journal:  BMJ       Date:  2011-01-25

6.  The impact of age-related macular degeneration on health status utility values.

Authors:  Mireia Espallargues; Carolyn J Czoski-Murray; Nicholas J Bansback; Jill Carlton; Grace M Lewis; Lindsey A Hughes; Christopher S Brand; John E Brazier
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-11       Impact factor: 4.799

7.  Value-based pricing: incentive for innovation or zero net benefit?

Authors:  Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

8.  Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.

Authors:  Joshua Pink; Steven Lane; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2012-05       Impact factor: 4.981

9.  Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

Authors:  Jim Chilcott; Chris McCabe; Paul Tappenden; Anthony O'Hagan; Nicola J Cooper; Keith Abrams; Karl Claxton; David H Miller
Journal:  BMJ       Date:  2003-03-08

10.  Whither trial-based economic evaluation for health care decision making?

Authors:  Mark J Sculpher; Karl Claxton; Mike Drummond; Chris McCabe
Journal:  Health Econ       Date:  2006-07       Impact factor: 3.046

View more
  2 in total

Review 1.  Role of the pharmacist in reducing healthcare costs: current insights.

Authors:  Kieran Dalton; Stephen Byrne
Journal:  Integr Pharm Res Pract       Date:  2017-01-25

2.  Cost-outcome description of clinical pharmacist interventions in a university teaching hospital.

Authors:  James Gallagher; Stephen Byrne; Noel Woods; Deirdre Lynch; Suzanne McCarthy
Journal:  BMC Health Serv Res       Date:  2014-04-17       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.